Personalis Inc (PSNL) USD0.0001

Sell:$3.40Buy:$4.01$0.02 (0.42%)

NASDAQ:0.18%
Market closed | Prices delayed by at least 15 minutes
Sell:$3.40
Buy:$4.01
Change:$0.02 (0.42%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$3.40
Buy:$4.01
Change:$0.02 (0.42%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.

Key people

Christopher M. Hall
President, Chief Executive Officer, Director
Aaron Tachibana
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Richard Chen
Executive Vice President - Research and Development, Chief Medical Officer
Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Karin Eastham
Independent Chairman of the Board
Olivia K. Bloom
Independent Director
A. Blaine Bowman
Independent Director
Woodrow A. Myers
Independent Director
Lonnie Shoff
Independent Director
Click to see more

Key facts

  • EPIC
    PSNL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US71535D1063
  • Market cap
    $365.41m
  • Employees
    229
  • Shares in issue
    88.26m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.